PMI

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

Wall Street analysts forecast PMI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMI is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Picard Medical Inc revenue for the last quarter amounts to 1.19M USD, increased 34.73 % YoY.

Picard Medical Inc. EPS for the last quarter amounts to -0.14 USD, increased 40.00 % YoY.

Picard Medical Inc (PMI) has 75 emplpoyees as of December 15 2025.

Today PMI has the market capitalization of 174.67M USD.